行情

NVIV

NVIV

InVivo
NASDAQ

实时行情|Nasdaq Last Sale

0.1600
+0.0079
+5.19%
盘后: 0.1690 +0.009 +5.63% 18:49 12/06 EST
开盘
0.1543
昨收
0.1521
最高
0.1649
最低
0.1490
成交量
47.97万
成交额
--
52周最高
2.060
52周最低
0.1231
市值
264.31万
市盈率(TTM)
-0.1352
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NVIV 新闻

  • 意大利最大商业银行拟裁员8000人
  • 新浪财经.3天前
  • 意大利总理支持欧洲稳定机制改革 遭反对党批评
  • 中国新闻网.3天前
  • 韩2019网购销售额破100万亿韩元 披萨炸鸡交易额剧增
  • 中国新闻网.3天前
  • 意大利再次修正2020财政预算案 推多项惠民政策
  • 中国新闻网.3天前

更多

所属板块

先进医疗设备和技术
+0.75%
医疗设备和用品
+0.57%

热门股票

名称
价格
涨跌幅

NVIV 简况

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company's approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.
展开

Webull提供Invivo Therapeutics Holdings Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。